NEWARK, NJ – December 5, 2018: Rafael Holdings, Inc. (NYSE American: RFL) today announced that its Chief Financial Officer, David Polinsky, will present an overview of the Company’s business and strategy at the 11th annual LD Micro Main Event on Thursday, December 6th at 7:30 AM PST / 10:30 AM EST. 

Rafael Holdings holds commercial real estate assets and interests in pharmaceutical companies, including Rafael Pharmaceuticals.  Rafael Pharmaceuticals, Inc. is a privately held clinical-stage, metabolic oncology therapeutics company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its first-in-class clinical lead compound, CPI-613 is being evaluated in multiple clinical studies including Phase III trials for pancreatic cancer and acute myeloid leukemia (AML). 

A webcast of the presentation will be available here  http://wsw.com/webcast/ldmicro15/rfl/ during the conference and for 90 days thereafter. The presentation slides will also be available for download in the investor relations section of the Rafael Holdings website, www.rafaelholdings.com.

About Rafael Holdings, Inc.:

Rafael Holdings holds commercial real estate assets and interests in two clinical stage pharmaceutical companies. The real estate holdings consist of properties in Newark and Piscataway, New Jersey and Jerusalem, Israel. The pharmaceutical holdings consist of interests in Rafael Pharmaceuticals, Inc. and a majority stake in Lipomedix Pharmaceuticals Ltd. Both are focused on development and commercialization of drugs in the oncology space. For more information, visit www.rafaelholdings.com